Effects of administration of omega-3 fatty acids with or without vitamin E supplementation on adiponectin gene expression in PBMCs and serum adiponectin and adipocyte fatty acid-binding protein levels in male patients with CAD

Anadolu Kardiyoloji Dergisi

Volumn 15, Issue 12, 2015, Pages 981-989

  Ramezani, Atena ^a,b   Koohdani, Fariba ^b   Djazayeri, Abolghasem ^b   Nematipour, Ebrahim ^b   Keshavarz, Seyed Ali ^b   Saboor Yaraghi, Ali Akbar ^b   Eshraghian, Mohammad Reza ^b   Yousefinejad, Abbas ^b   Javanbakht, Hassan ^b   Zarei, Mahnaz ^b   Gholamhosseini, Sanaz ^b   Djalali, Mahmoud ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipocyte fatty acid binding protein; Adiponectin; Coronary artery disease; Omega 3 fatty acids; Vitamin E

Indexed keywords

ADIPONECTIN; ALPHA TOCOPHEROL; FATTY ACID BINDING PROTEIN 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; ASCORBIC ACID; CHOLESTEROL; FOLIC ACID; PLACEBO; SELENIUM; ZINC; ADIPOQ PROTEIN, HUMAN;

ADULT; ANGIOCARDIOGRAPHY; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIP CIRCUMFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUTRITIONAL ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL ACTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ANTHROPOMETRIC PARAMETERS; BLOOD ANALYSIS; BODY MASS; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; FAT INTAKE; MACRONUTRIENT; BLOOD; DIETARY SUPPLEMENT; GENE EXPRESSION REGULATION;

ADIPONECTIN; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; VITAMIN E;

EID: 84994182439     PISSN: 13028723     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2015.5849     Document Type: Article

References (39)

1. World Health Organization, Cardiovascular Diseases (CVDs) FactSheet. 2011; Available from: http://wwwwhoint/mediacentre/factsheets/fs317/en/indexhtml.
2. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circ J 2005; 112: 3547-53. [CrossRef].
3. Fakhrzadeh H, Larijani B, Bandarian F, Adibi H, Samavat T, Malek Afzali H. The relationship between ischemic heart disease and coronary risk factors in population aged over 25 in Qazvin: A population-based study. J Qazvin Univ Med Sci 2005; 35: 26-34.
4. Gu D, Gupta A, Muntner P, Hu S, Duan X, Chen J, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation 2005; 112: 658-65. [CrossRef].
5. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 2010; 64: 1220-7. [CrossRef].
6. Go A, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circ J 2014; 129: e28-e292. [CrossRef].
7. Teo K, Lear S, Islam S, Mony P, Dehghan M, Li W, et al. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle-and low-income countries. The Prospective Urban Rural Epidemiology (PURE) Study. JAMA 2013; 309: 1613-21. [CrossRef].
8. Song J, Kwon N, Lee MH, Ko YG, Lee JH, Kim OY. Association of serum phospholipid PUFAs with cardiometabolic risk: beneficial effect of DHA on the suppression of vascular proliferation/inflammation. Clin Biochem 2014; 47: 361-8. [CrossRef].
9. Ferrari R. Revising common beliefs in the management of stable CAD. Nat Rev Cardiol 2013; 10: 65-6. [CrossRef].
10. Go A, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circ J 2013; 127: e6-e245. [CrossRef].
11. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003; 23: 151-2. [CrossRef].
12. Fisman E, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol 2014; 13: 2-10. [CrossRef].
13. Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J. Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease. Atherosclerosis 2012; 221: 514-20. [CrossRef].
14. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009; 10: 269-79. [CrossRef].
15. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1918-25. [CrossRef].
16. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007; 49: 531-8. [CrossRef].
17. Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity. Int J Inflamm 2011; 2011: 1-8.
18. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007; 74: 8-11. [CrossRef].
19. Wang Y, Zheng A, Yan Y, Song F, Kong Q, Qin S, et al. Association between HMW adiponectin, HMW-total adiponectin ratio and early-onset coronary artery disease in Chinese population. Atherosclerosis 2014; 235: 392-7 [CrossRef].
20. Miyazaki T, Hiki M, Shimada K, Kume A, Kiyanagi T, Sumiyoshi K. The High molecular weight adiponectin level is associated with the atherogenic lipoprotein profiles in healthy Japanese males. J Atheroscler Thromb 2014; 12: 273-7. [CrossRef].
21. Gray B, Swick J, Ronnenberg AG. Vitamin E and adiponectin: proposed mechanism for vitamin E-induced improvement in insulin sensitivity. Nutr Rev 2011; 69: 155-61. [CrossRef].
22. Jin J, Peng DQ, Yuan SG, Zhao SP, Ning XH, Wang SH, et al. Serum adipocyte fatty acid binding proteins and adiponectin in patients with coronary artery disease: the significance of A-FABP/adiponectin ratio. Clin Chim Acta 2010; 411: 1761-5. [CrossRef].
23. Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M, et al. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. PloS One 2011; 6: e19115. [CrossRef].
24. Van Berendoncks AM, Conraads VM. Functional adiponectin resistance and exercise intolerance in heart failure. Curr Heart Fail Rep 2011; 8: 113-22. [CrossRef].
25. Kratz M, Swarbrick MM, Callahan HS, Matthys CC, Havel PJ, Weigle DS. Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. Am J Clin Nutr 2008; 87: 347-53.
26. Komura N, Maeda N, Mori T, Kihara S, Nakatsuji H, Hirata A. Adiponectin protein exists in aortic endothelial cells. PloS One 2013; 8: e71271. [CrossRef].
27. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005; 111: 747-53. [CrossRef].
28. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25: 2062-8. [CrossRef].
29. Mazaki-Tovi M, Abood SK, Schenck PA. Fish oil supplementation increases concentration of adiponectin in healthy dogs. JSAP 2014; 55: 247-53. [CrossRef].
30. Wolf AM, Wolf D, Avila MA, Moschen AR, Berasain C, Enrich B, et al. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatology 2006; 44: 537-43. [CrossRef].
31. Tsai JS, Chen CY, Chen YL, Chuang LM. Rosiglitazone inhibits monocyte/macrophage adhesion through de novo adiponectin production in human monocytes. J Cell Biochem 2010; 110: 1410-9. [CrossRef].
32. Tsai JS, Guo FR, Chen SC, Lue BH, Chiu TY, Chen CY, et al. Smokers show reduced circulating adiponectin levels and adiponectin mRNA expression in peripheral blood mononuclear cells. Atherosclerosis 2011; 218: 168-73. [CrossRef].
33. Deemer SE, King GA, Hickey MS, Melby CL. Omega-3 fatty acid supplementation does not alter insulin sensitivity or serum adiponectin in healthy hispanic women. FASEB J 2013; 27: 1057-8.
34. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006; 55: 924-8. [CrossRef].
35. Landrier JF, Gouranton E, El Yazidi C, Malezet C, Balaguer P, Borel P, et al. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology 2009; 150: 5318-25. [CrossRef].
36. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-63. [CrossRef].
37. Komura N, Kihara S, Sonoda M, Kumada M, Fujita K, Hiuge A, et al. Clinical significance of high-molecular weight form of adiponectin in male patients with coronary artery disease. Circulation J 2008; 72: 23-8. [CrossRef].
38. Doi M, Miyoshi T, Hirohata S, Nakamura K, Usui S, Takeda K, et al. Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol 2011; 10: 1-7. [CrossRef].
39. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, et al. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 2010; 211: 164-9. [CrossRef].